New possibilities of biomarker‐based predictive technologies for Alzheimer's disease (AD) have become more reliable as well as more accessible. Standardized clinical recommendations and guidance for counseling and disclosure in this context are not yet well developed. Our scoping review identified publications from database searches in PubMed, PsycINFO, LIVIVO, and Web of Science. Inclusion criteria were: (1) information or counseling, (2) biomarkers and a type of cognitive impairment or AD, and (3) published between 2005 and 2024. We identified 63 articles and synthesized them along the categories of staged information provision: pre‐test counseling, disclosure, and post‐disclosure follow‐up. Most publications referred to the context of disclosure (48), followed by pre‐test counseling (33), and post‐disclosure follow‐up (31). Some publications referred to all stages of counseling (17). Our findings highlight the need to further develop and specify comprehensive and standardized guidelines for counseling, disclosure, and post‐disclosure follow‐up in the context of AD biomarker testing.Highlights New possibilities of biomarker‐based predictive technologies for Alzheimer's disease (AD) have become more reliable and also more accessible. However, clinical recommendations and guidance for counseling and disclosure in the context of AD biomarker testing are currently not well developed. We carried out a scoping review with the aim to generate an overview of the scientific literature and guidance available regarding counseling, biomarker test result and dementia risk disclosure, and clinical management prior to and in the course of a biomarker‐based diagnosis in early stages of AD. We identified 63 relevant articles. Most publications referred to the context of disclosure (48), followed by pre‐test counseling (33), and post‐disclosure follow‐up (31). Some publications referred to all stages of counseling (17). Our findings highlight the urgent need for national and international consensus guidelines for comprehensive and staged counseling and disclosure practices. While most publications identify relevant ethical challenges posed for counseling practices in the context of AD biomarker testing, they rarely present any practical recommendations for clinicians, on how and what to counsel on a concrete level.

中文翻译：

---

预测性阿尔茨海默病诊断的咨询和披露实践：范围综述


基于生物标志物的阿尔茨海默病 （AD） 预测技术的新可能性变得更加可靠，也更容易获得。在这种情况下，关于咨询和披露的标准化临床建议和指导尚未得到很好的发展。我们的范围综述从 PubMed、PsycINFO、LIVIVO 和 Web of Science 的数据库检索中确定了出版物。纳入标准是：（1） 信息或咨询，（2） 生物标志物和一种认知障碍或 AD，以及 （3） 在 2005 年至 2024 年间发表。我们确定了 63 篇文章，并按照分阶段信息提供的类别对其进行了综合：测试前咨询、披露和披露后随访。大多数出版物提到了披露的背景 （48），其次是测试前咨询 （33） 和披露后随访 （31）。一些出版物提到了咨询的所有阶段 （17）。我们的研究结果强调了在 AD 生物标志物测试的背景下进一步制定和指定咨询、披露和披露后随访的全面和标准化指南的必要性。亮点 基于生物标志物的阿尔茨海默病 （AD） 预测技术的新可能性变得更加可靠，也更容易获得。然而，目前还没有很好的 AD 生物标志物检测背景下咨询和披露的临床建议和指导。我们进行了一项范围综述，旨在概述关于咨询、生物标志物检测结果和痴呆风险披露以及 AD 早期基于生物标志物的诊断之前和过程中的临床管理的科学文献和指南。我们确定了 63 篇相关文章。 大多数出版物提到了披露的背景 （48），其次是测试前咨询 （33） 和披露后随访 （31）。一些出版物提到了咨询的所有阶段 （17）。我们的研究结果突出了迫切需要国家和国际共识指南，以实现全面和分阶段的咨询和披露实践。虽然大多数出版物确定了在 AD 生物标志物检测的背景下对咨询实践构成的相关道德挑战，但它们很少为临床医生提供任何实用的建议，关于如何以及在具体层面上提供什么咨询。